Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of oncology, hospital antibiotics and hospital antifungals. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and two oncology drug candidates in development. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 as a spin-out from Roche and is headquartered in the heart of the life sciences hub of Basel. The Basilea group currently has 220 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.

People are at the heart of everything we do. We strive towards making a difference to patients. With expertise, care and persistence. We aim to be a leading provider of innovative medicines. For the benefit of patients.